Walter Hanel

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Year:

2026

Introduction High-dose systemic methotrexate (HD-MTX) in doses ≥ 3 g/m 2 is the cornerstone of treatment for central nervous system (CNS) lymphomas and prophylaxis for patients with high-risk of CNS relapse. Its administration requires extensive supportive care until serum clearance is achieved. Risk factors for delayed methotrexate (MTX) clearance and renal injury are well-characterized and include baseline renal function, age, and hypoalbuminemia. Data assessing characteristics associated with slow terminal clearance are lacking. Methods We performed a single-center, retrospective cohort study between 1/2015 to 10/2023 to evaluate characteristics associated with the rate of MTX clearance in the 72 h after serum MTX levels decline to below 0.2 µmol/L in adult patients with lymphoma who received MTX at doses ≥ 3 g/m 2 . MTX administration was evaluated at the cycle level with slow terminal clearance (STC) defined as > 72 h to clear from 30 kg/m 2 , first MTX level > 10.0 µmol/L, and acute kidney injury (AKI) after MTX administration were significantly associated with STC. Conclusion Utilizing clinically and statistically significant variables from our analyses, we advocate for the development and validation of a model to inform supportive care management once MTX levels decline below 0.2 µmol/L.

Year:

2026

Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. Experimental Design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 (SOX11) and Cyclin D1 (CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL’s biological and pathologic features. Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system. Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.

Year:

2025

Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. Experimental Design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 ( SOX11 ) and Cyclin D1 ( CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL’s biological and pathologic features. Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system. Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Collaborators (22)

Laura Hilton

Staff Scientist

Simon Fraser University

CANADA
View details

Alice Mims

Ohio State University

UNITED STATES
View details

Cem Meydan

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Robert Baiocchi

-

UNITED STATES
View details

Parvathi Ranganathan

Associate Professor with Tenure

Ohio State University

UNITED STATES
View details

Rosa Lapalombella

Ohio State University

UNITED STATES
View details

John Reneau

Ohio State University

UNITED STATES
View details

Lapo Alinari

Ohio State University

UNITED STATES
View details

XIAOLI ZHANG

Professor

University of South Florida

UNITED STATES
View details

chunhua song

Associate Professor

Ohio State University

UNITED STATES
View details

Narendranath Epperla

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Satishkumar Singh

Ohio State University

UNITED STATES
View details

Yazeed Sawalha

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Samir Parekh

Director, Center of Excellence for Multiple Myeloma

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Wing Keung Chan

Assistant Professor

Ohio State University

UNITED STATES
View details

Robert Faryabi

Associate Professor

University of Pennsylvania

UNITED STATES
View details

David Bond

Associate Professor

Ohio State University

UNITED STATES
View details

Blake Peterson

Professor and Chair

Ohio State University

UNITED STATES
View details

Lalit Sehgal

Associate Professor

Ohio State University

UNITED STATES
View details

Violetta Leshchenko

Senior Scientist

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Timothy Voorhees

Associate Professor of Clinical Internal Medicine

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Christopher Mason

Professor

Weill Cornell Medical College

UNITED STATES
View details